Online inquiry

IVTScrip™ mRNA-Anti-PCSK9, LY-3015014(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ10542MR)

This product GTTS-WQ10542MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets PCSK9 gene. The antibody can be applied in Heterozygous familial hypercholesterolemia (HeFH) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_174936.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 255738
UniProt ID Q8NBP7
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PCSK9, LY-3015014(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ10542MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3878MR IVTScrip™ mRNA-Anti-PDCD1, BCD-100(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BCD-100
GTTS-WQ8288MR IVTScrip™ mRNA-Anti-GHR, HM10560A(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA HM10560A
GTTS-WQ9004MR IVTScrip™ mRNA-Anti-IL13, IMA-638(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA IMA-638
GTTS-WQ8789MR IVTScrip™ mRNA-Anti-PCSK9, IBI-306(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA IBI-306
GTTS-WQ10846MR IVTScrip™ mRNA-Anti-FOLR1, M9346A(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA M9346A
GTTS-WQ11683MR IVTScrip™ mRNA-Anti-influenza B virus hemagglutinin, MHAB5553A(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MHAB5553A
GTTS-WQ13921MR IVTScrip™ mRNA-Anti-INHBA, REGN2477(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA REGN2477
GTTS-WQ12112MR IVTScrip™ mRNA-Anti-FOLR1, MORAb-003(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MORAb-003
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW